Company Overview of Eleven Biotherapeutics, Inc.
Eleven Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, is engaged in the discovery and development of protein therapeutics to treat eye diseases primarily in the United States. The company develops its therapeutics through AMP-Rx, a proprietary protein engineering platform. Its principal product candidate includes the EBI-005, a novel IL-1 receptor antagonist that is in Phase III clinical program for the treatment of moderate to severe dry eye diseases; and in Phase II clinical trial for the treatment of allergic conjunctivitis. The company’s preclinical product candidates comprise EBI-029, a novel inhibitor of the cytokine IL-6 for the treatment of retinal diseases, such ...
215 First Street
Cambridge, MA 02142
Founded in 2008
Key Executives for Eleven Biotherapeutics, Inc.
Chief Executive Officer
Total Annual Compensation: $459.4K
Chief Development Officer
Total Annual Compensation: $198.0K
Chief Scientific Officer
Total Annual Compensation: $344.5K
Compensation as of Fiscal Year 2013.
Eleven Biotherapeutics, Inc. Key Developments
Eleven Biotherapeutics Appoints Wendy L. Dixon to Board of Directors
Oct 23 14
Eleven Biotherapeutics announced the appointment of Wendy L. Dixon, PhD, former Chief Marketing Officer and President of Global Marketing for Bristol Myers Squibb, to the company's Board of Directors. Dr. Dixon brings 35 years of industry experience to the Eleven Biotherapeutics Board of Directors. Most recently, she was a senior advisor to The Monitor Group, now Monitor Deloitte, from 2010 to 2012.
Eleven Biotherapeutics, Inc. Announces Results from Phase II Allergic Conjunctivitis Study
Oct 9 14
Eleven Biotherapeutics, Inc. has announced results from a Phase II study of its lead drug candidate, EBI-005, in patients with moderate to severe allergic conjunctivitis. The company ran this Phase II study using two distinct repetitive allergen challenge models: a modified Conjunctival Allergen Provocation Test (CAPT) model; and a modified Environmental Exposure Chamber (EEC) model. In the CAPT model, patients treated with EBI-005 showed statistically significant improvements in mean change from baseline in patient reported ocular itching compared to vehicle-control, one of the secondary endpoints pre-specified in the statistical analysis plan, at the second to last (p = 0.033) and final (p = 0.045) assessment time points. This Phase II study did not meet the primary endpoint of reduction in mean ocular itching in patients treated with EBI-005 compared to vehicle-control in the EEC model.
Eleven Biotherapeutics, Inc. - Special Call
Oct 2 14
To discuss the top-line Phase 2 clinical study results of EBI-005 in allergic conjunctivitis
Similar Private Companies By Industry
Recent Private Companies Transactions
December 4, 2013
Most Searched Private Companies
Sponsored Financial Commentaries